Videos

ALS Update in Treatment & Clinical Trials by Dr. Jinsy A. Andrews. Dr. Jinsy is the Associate Professor of Neurology, in the Division of Neuromuscular Medicine & the Director of Neuromuscular Clinical Trials, Columbia University Irving Medical Center.

In this #ExpertTalk series, Dr. John Landers, Professor of Neurology at UMass Chan Medical School talks about Crowdsourcing: Accelerating Genetic Findings through the #ALS Compute Project.

In this episode of #ALS #experttalks, Dr. Merit Cudkowicz speaks about 2024 ALS Outlook. Dr. Merit Cudkowicz is the Director, Sean M. Healey & AMG Center for ALS, Chief of Neurology at Massachusetts General Hospital, Director & the Julieanne Dorn Professor of Neurology, at Harvard Medical School.

Join us for an inspiring and informative expert talk on 2024 ALS Reversals Update by Dr. Richard Bedlack M.D., Ph.D, Dr. Bedlack is a Stewart, Hughes and Wendt Distinguished Professor of ALS Duke & Director of the Duke ALS Clinic.

Join us for an inspiring and informative expert talk on How to Slow ALS Progression with Dr. Eduardo Locatelli, MD. Dr. Eduardo Locatelli, M.D., serves as the Medical Director of the Nova Southeastern University (NSU) Health Neuroscience Institute. Prior to this role, he played a key leadership role at Holy Cross Hospital (HCH) in Fort Lauderdale, where he spearheaded the establishment and growth of the Phil Smith Neuroscience Institute.

Stephen Goutman, MD, MS, FAAN is an Associate Professor in the Department of Neurology, Director of the Pranger Amyotrophic Lateral Sclerosis Clinic, and Associate Director of the ALS Center of Excellence at Michigan Medicine. After obtaining a degree in neuroscience at the Johns Hopkins University (Baltimore, MD), Dr. Goutman completed his medical degree at the University of Chicago Pritzker School of Medicine (Chicago, IL) and his neurology residency and neuromuscular fellowship at Cleveland Clinic (Cleveland, OH). He received a Master’s in Clinical Research Design and Statistical Analysis at the University of Michigan (Ann Arbor, MI). Inspired by his patients, Dr. Goutman’s research focuses on identifying new mechanisms and therapies for ALS. Specifically, he has been seeking to understand the genetic and environmental interactions that alter susceptibility to ALS, especially in the State of Michigan, which has some of the highest rates of ALS in the country. With funding from the National Institutes of Health, the Centers for Disease Control and Prevention, and the ALS Association, he is discovering environmental risk factors associated with the onset and progression of ALS by collecting epidemiologic exposure surveys and biofluids from individuals with and without ALS. The ultimate goal is to one day make ALS a preventable disease. Dr. Goutman serves as the site principal investigator of several multi-site clinical trials focused on identifying new ALS treatments. He is an active participant with the Northeast ALS Consortium (NEALS) and has close to a decade of experience leading ALS clinical trials at University of Michigan.